Roche Buy Roche is shelling out $4.3 billion for Spark Therapeutics, a gene therapy outfit that will help beef up the Swiss firm's haemophilia portfolio. Roche CEO Severin Schwan: "Spark Therapeutics haemophilia A programme could become a new therapeutic option for people living with this disease." Reuters